REITHERA’s Post

The cell and gene therapy (CGT) market is set to skyrocket, but navigating its challenges, especially in product preservation, is critical. Traditional liquid nitrogen freezers come with significant risks and costs. Mechanical freezers are emerging as a safer, more efficient alternative, crucial for protecting fragile, high-value CGT products and driving innovation. Read the full article written by Kenan Moss, Cell & Gene Therapy Application Specialist with PHC Corporation of North America here: https://lnkd.in/eFnd4jrt #CellAndGeneTherapy #CGT #Biotech #LifeSciences #GeneTherapy #CellTherapy #Biopharma #BiotechResearch #CGTInnovation

Here is a great piece highlighting the crucial role of preservation equipment in CGT research! 👏 Good work Kenan Moss! #PHCbi #weprotectscience #CellAndGeneTherapy #CGT #Biotech #LifeSciences #GeneTherapy #CellTherapy #Biopharma #BiotechResearch #CGTInnovation #ColdChain

📢 Revolutionary Automation System Cuts Costs and Errors in Cell and Gene Therapy Manufacturing 🤖 A vendor-agnostic automation system for cell and gene therapy manufacturing has been developed by Multiply Labs. 🔬 The system uses industry-standard equipment, reducing human errors and lowering manufacturing costs by approximately 70%. 💡 The automation technique can be added to existing processes without the need for redesigning. 🏭 Leading companies in the biopharma equipment space, such as GenScript and Thermo Fisher, are partnering with Multiply Labs. ⚙️ The automated process improves repeatability, decreases errors, and reduces necessary production space. ✅ The goal is to automate the major processing instruments used in cell and gene therapy manufacturing. #BioprocessUpdates #automation #celltherapy #genetherapy #manufacturing #vendoragnostic #industryequipment #reducinghamanerrors #loweringcosts #partnerships #biopharmaequipment #improvedrepeatability #decreasederrors #reducedspace #automatedinstruments ▷ Read the full article here: 📎 https://lnkd.in/dHrUUN3E

Really interesting chart below, AAV still dominant for gene therapy, but #LNP and other non viral approaches are definitely gaining momentum! Would be interesting to see this split for UK companies . I certainly know of more companies, but they tend to be at very early stages in their development. The explosion for LNP and other non viral approaches will come if someone really cracks targeting, or if their huge potential for gene editing/ writing takes off . Luckily CPI can support across AAV, LV, exosome and a huge range of non viral delivery technologies including LNP! #genetherapy #viralvectors #rna #drugdelivery #LetsInnovateTogether

The gene therapy landscape is evolving rapidly, with a diverse range of viral and non-viral delivery mechanisms being explored. While AAV currently dominates, we're seeing a growing interest in non-viral approaches like LNPs. This infographic offers a valuable snapshot of the current landscape and raises intriguing questions about the future of gene therapy. Is the next decade going to be the rise of non-viral gene therapies?  #GeneTherapy #Biotech #Investment #Innovation

Great info, as always, Spencer Knight! The viral vector landscape is as robust as ever. Every conversation I have with clients and potential clients creates a surge of enthusiasm, especially when the indications hit closer to home, as they have in the past few conversations. It makes the kind of cutting-edge, highly complex work seem less ethereal and more relevant when you know someone close who is waiting for the realization of its potential to unfold. Still, the careful selection of appropriate targets and the identification of relevant indications are crucial steps toward bringing these innovative treatments from research to clinical practice. We live at the intersection of cutting-edge science and medicine, where many of our colleagues hold the potential to revolutionize how we treat and understand many serious diseases. What an incredible time period. What miracles will we be alive to witness, I wonder? #GeneTherapy #ViralVectors #Science

𝐕𝐢𝐫𝐚𝐥 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 – 𝐇𝐨𝐰 𝐂𝐚𝐧 𝐭𝐡𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐃𝐫𝐢𝐯𝐞 𝐃𝐨𝐰𝐧 𝐭𝐡𝐞 𝐂𝐨𝐬𝐭 𝐨𝐟 𝐆𝐨𝐨𝐝𝐬 𝐭𝐨 𝐁𝐞𝐭𝐭𝐞𝐫 𝐒𝐞𝐫𝐯𝐞 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬? Recent approvals of viral gene therapies have reached record costs, with HEMGENIX priced at $3.5M per dose. How can the industry lower these costs? Emmanuelle Cameau Cytiva explores how process development, cost modeling, and process intensification can drive down the cost of viral gene therapies, making them more accessible to patients in need. Discover innovative strategies to enhance efficiency and reduce expenses without compromising quality. Dive into the future of affordable 𝐠𝐞𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 today. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: https://lnkd.in/g632RKEd #GeneTherapy #Biotech #HealthcareInnovation #CostReduction #ProcessDevelopment #MedicalBreakthroughs #PatientCare #Biopharma #FutureOfMedicine #GeneTherapyCosts #HealthcareCosts #InnovationInHealthcare #AffordableHealthcare #LifeSciences #ViralTherapy

Increasing efficiency in #AAV-based #genetherapy production: platform optimization with #multiserotype #AAVaffinitycapture As the gene therapy field advances, speed-to-market is becoming more and more essential. The necessary reduction in development timelines can be realized by leveraging platform-based tools for #AAVmanufacturing. In this #article, an off-the-shelf solution for #AAV production developed by a #CDMO, with a focus on the #AAVcapturesteps in the downstream process, is discussed Read at your convenience below:

The limitations of plasmid DNA in AAV manufacturing are a bottleneck for gene therapy applications. Touchlight's enzymatically synthesised dbDNA™ overcomes these hurdles, offering a high-fidelity, safer, and more efficient alternative. Read one of our newest articles, "Transforming the Economics of AAV Manufacture While Optimizing Quality with dbDNA" to discover how Touchlight is paving the way for safer and more efficient gene therapy manufacturing: Tom Merritt #biotechnology #pharma #biotech #genetherapy #dbDNA

Delving into the New Era of Gene Editing in Healthcare | NEJM presents a compelling exploration of the advancements in gene editing within medical science. This groundbreaking technology has the potential to revolutionize treatment options and enhance patient outcomes. The article discusses the profound impact of gene editing on the field of medicine, highlighting its role in driving innovation and progress. With the continuous evolution of gene editing techniques, the future of healthcare looks promising and filled with possibilities. #MedicalInnovation #GeneticAdvancements https://buff.ly/3Jxkexi